<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109081">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672164</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOT-14</org_study_id>
    <nct_id>NCT01672164</nct_id>
  </id_info>
  <brief_title>Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients</brief_title>
  <acronym>CTOT-14</acronym>
  <official_title>Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood &amp; Urine Monitoring Study of Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main focus of this study is to develop blood and/or urine tests that will help to detect
      early signs of rejection in people who have had a liver transplant. Researchers will examine
      blood, urine, and tissue samples and try to identify markers for certain conditions such as
      rejection, response to therapy, and scarring of the liver.  Additionally, researchers would
      like to identify biomarkers that can detect damage to the native kidneys before blood levels
      of creatinine rises.  By studying gene expression, researchers hope to be able to diagnose
      these conditions earlier and improve liver survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Acute Rejection</measure>
    <time_frame>3 months after liver transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint is the incidence of biopsy proven AR at 3, 12 and 24 months after LT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Rejection</measure>
    <time_frame>12 months after liver transplant</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Rejection</measure>
    <time_frame>24 months after liver transplant</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of acute rejection</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12):</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Severity (initial grade, steroid-responsive vs. refractory by biopsy) and clinical/biochemical resolution following treatment of AR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Hepatitis-C Virus (HCV-R)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence, severity (grade, stage), and treatment (requirement for, response rates) of HCV-R</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Kidney Disease(CKD)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence, severity (stage, need for renal replacement therapy or kidney transplantation), and response to treatment (CNI reduction/withdrawal Â± MPA or mTOR) of CKD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death, graft loss, and need for liver retransplantation</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of opportunistic infections, malignancy, and cardiovascular complications</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression profiles of peripheral blood (AR, HCV-R, CKD)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression profiles of liver biopsies (AR, HCV-R)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression profiles of plasma ( AR, HCV-R, CKD)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression profiles of urine (CKD)</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microRNA Profiling Plasma &amp; Cells</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiparameter Flow Cytometry - Viral Pathogens</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Monitoring - EBV &amp; CMV</measure>
    <time_frame>Baseline (Visit 1) to Month 24 (Visit 12)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Proteogenomic Monitoring in Liver Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Liver Transplant Recipients</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma, serum, urine supernatant, urine pellet and tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Liver Transplant Recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects undergoing primary deceased-donor or living donor liver transplantation.

          -  Subject must be able to understand and provide informed consent.

        Exclusion Criteria:

          -  Need for combined organ transplantation

          -  Previous solid organ and/or islet cell transplantation

          -  Infection with HIV

          -  Allergy to Iodine

          -  Inability or unwillingness of a participant to comply with study protocol

          -  Any condition that, in the opinion of the investigator, would interfere with the
             participant's ability to comply with study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Levitsky, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MICHAEL ABECASSIS, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Univ.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merideth Brown, MS</last_name>
    <email>brownmeri@niaid.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Leonard</last_name>
      <email>leonard.michael@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adyr Moss, MD</last_name>
      <email>moss.adyr@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adyr Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Charette, RN, BSN, CCRC</last_name>
      <email>jane-charette@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Josh Levitsky, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Mojica</last_name>
      <email>Janice.Mojica@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Schiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Terry</last_name>
      <email>terrym@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Charles Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Johnson</last_name>
      <email>cronan@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Chavin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Primeaux</last_name>
      <email>Sharon.Primeaux@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Sumeet Asrani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
